AIM ImmunoTech Inc.
AIM
$0.12
-$0.0034-2.76%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.55% | 19.64% | 23.72% | 44.29% | 44.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.55% | 19.64% | 23.72% | 44.29% | 44.03% |
| Cost of Revenue | 20.00% | -- | -27.54% | -71.23% | -90.68% |
| Gross Profit | -5.52% | -14.88% | 64.37% | 2,766.67% | 186.70% |
| SG&A Expenses | 49.31% | 69.39% | 73.75% | 64.70% | 16.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.80% | 44.49% | 58.08% | 60.08% | 17.32% |
| Operating Income | -18.97% | -44.68% | -58.33% | -60.19% | -17.15% |
| Income Before Tax | -15.18% | -44.98% | -61.35% | -48.94% | 0.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.18% | -44.98% | -61.35% | -48.94% | 0.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.18% | -44.98% | -61.35% | -48.94% | 0.61% |
| EBIT | -18.97% | -44.68% | -58.33% | -60.19% | -17.15% |
| EBITDA | -19.73% | -45.80% | -59.22% | -61.07% | -17.03% |
| EPS Basic | -10.42% | -42.16% | -58.95% | -47.00% | 1.49% |
| Normalized Basic EPS | -13.07% | -43.28% | -63.40% | -62.07% | -19.56% |
| EPS Diluted | -9.85% | -41.21% | -57.81% | -48.09% | 0.48% |
| Normalized Diluted EPS | -13.07% | -43.28% | -63.40% | -62.07% | -19.56% |
| Average Basic Shares Outstanding | 7.92% | 3.55% | 1.45% | 1.12% | 0.80% |
| Average Diluted Shares Outstanding | 7.92% | 3.55% | 1.45% | 1.12% | 0.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
